Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials
Abstract Background Cutaneous adverse effects (AEs) are common following the phosphoinositide‐3‐kinase (PI3K) inhibitors treatment. We aim to estimate the incidence and risk of PI3K inhibitor‐related cutaneous AEs. Methods The protocol was submitted to the PROSPERO registry. We searched ClinicalTria...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5153 |